Experiments in vitro with the cancer cell line, which was derived from this xenograft tumor, showed that the blockade of AXL and SMO, of SMO and EGFR, and, more efficiently, of AXL and EGFR was able to revert the resistance to EGFR. The gene discussed is AXL; the disease is cancer.